Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy

Background  Emicizumab, a bispecific monoclonal antibody for hemophilia A (HA), has strong pharmacodynamic effects in several coagulation assays resulting in dosing difficulties with Factor VIII (FVIII) concentrates during bleeding emergencies. Materials and Methods Single and multiple regression mo...

Full description

Bibliographic Details
Main Authors: Yuki Hatayama PhD, Toru Motokura MD, PhD, Yuzuru Hosoda MD, Sayaka Suzuki MD, Hiroya Namba, Konami Kato, Nao Kojima, Takuya Horie PhD, Takuya Iwamoto, Noriko Yamashita, Hitomi Ichikawa, Tetsuya Fukuda MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2022-02-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296221082992

Internet

https://doi.org/10.1177/10760296221082992

Similar Items